GlobalGov › Germany › Pharmaceuticals › Solicitation

Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Colecalciferol (A11CC05), exkl. RX-Sortiment.

Health · Germany government procurement

GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

January 25, 2027
Response Due
Active
Status

Opportunity Overview

Germany – Pharmaceutical products – Conclusion of a non-exclusive discount agreement pursuant to Section 130a Paragraph 8 of the German Social Code, Book V (SGB V) for medicinal products containing the active ingredient cholecalciferol (A11CC05), excluding the RX range.

This is one of 1,390 active Germany Pharmaceuticals opportunities most of your competitors will never see.

Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start Free

Solicitation Details

Issuing agencyHealth
CountryGermany
CategoryPharmaceuticals
PublishedFebruary 06, 2025
Procurement stageActive solicitation
Response dueJanuary 25, 2027
StatusOpen — accepting responses
TranslationTranslated from German by GlobalGov’s translation pipeline
Official sourceView original notice
Last verifiedAugust 10, 2026

Source: Tenders Electronic Daily (TED), © European Union. Notice content reused under Commission Decision 2011/833/EU; editorial content licensed CC BY 4.0. GlobalGov is not affiliated with the European Union.

Germany market overview →Pharmaceuticals tenders in Germany →Browse all categories →

Related Opportunities in Germany

Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit der Wirkstoffkombination aus Lamivudin, Tenofovirdisoproxil und Doravirin (ATC-Code: J05AR24).
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Oxycodon/Naloxon (ATC-Code nach WHO: N02AA55)
Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-02- Elvitegravir/Cobicistat/Emtricitabin/Tenofoviralafenamidfumarat (Genvoya(R))
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Naproxen/Esomeprazol (ATC-Code nach WHO: M01AE52)
Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Omalizumab (ATC-Code: R03DX05).
Germany – Pharmaceutical products – Arzneimittel mit dem Wirkstoff Fluorouracil (ATC: D11AF05)
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Certolizumab pegol, ATC L04AB05
Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Posaconazol (ATC J02AC04).

See every Germany Pharmaceuticals opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free Germany Pharmaceuticals intelligence report in your inbox

A personalized report on Germany Pharmaceuticals opportunities, emailed in 5-10 minutes. One per month, no account needed.